{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:10:13Z","timestamp":1770477013334,"version":"3.49.0"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The compartmental pharmacokinetics of anidulafungin (VER-002; formerly LY303366) in plasma were characterized with normal rabbits, and the relationships between drug concentrations and antifungal efficacy were assessed in clinically applicable infection models in persistently neutropenic animals. At intravenous dosages ranging from 0.1 to 20 mg\/kg of body weight, anidulafungin demonstrated linear plasma pharmacokinetics that fitted best to a three-compartment open pharmacokinetic model. Following administration over 7 days, the mean (\u00b1 standard error of the mean) peak plasma concentration (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ) increased from 0.46 \u00b1 0.02 \u03bcg\/ml at 0.1 mg\/kg to 63.02 \u00b1 2.93 \u03bcg\/ml at 20 mg\/kg, and the mean area under the concentration-time curve from 0 h to infinity (AUC\n            <jats:sub>0\u2013\u221e<\/jats:sub>\n            ) rose from 0.71 \u00b1 0.04 to 208.80 \u00b1 24.21 \u03bcg \u00b7 h\/ml. The mean apparent volume of distribution at steady state (\n            <jats:italic>V<\/jats:italic>\n            <jats:sub>ss<\/jats:sub>\n            ) ranged from 0.953 \u00b1 0.05 to 1.636 \u00b1 0.22 liter\/kg (nonsignificant [NS]), and clearance ranged from 0.107 \u00b1 0.01 to 0.149 \u00b1 0.00 liter\/kg\/h (NS). Except for a significant prolongation of the terminal half-life and a trend toward an increased\n            <jats:italic>V<\/jats:italic>\n            <jats:sub>ss<\/jats:sub>\n            at the higher end of the dosage range after multiple doses, no significant differences in pharmacokinetic parameters were noted in comparison to single-dose administration. Concentrations in tissue at trough after multiple dosing (0.1 to 10 mg\/kg\/day) were highest in lung and liver (0.85 \u00b1 0.16 to 32.64 \u00b1 2.03 and 0.32 \u00b1 0.05 to 43.76 \u00b1 1.62 \u03bcg\/g, respectively), followed by spleen and kidney (0.24 \u00b1 0.65 to 21.74 \u00b1 1.86 and &lt;0.20 to 16.92 \u00b1 0.56, respectively). Measurable concentrations in brain tissue were found at dosages of \u22650.5 mg\/kg (0.24 \u00b1 0.02 to 3.90 \u00b1 0.25). Implementation of optimal plasma sampling in persistently neutropenic rabbit infection models of disseminated candidiasis and pulmonary aspergillosis based on the Bayesian approach and model parameters from normal animals as priors revealed a significantly slower clearance (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05 for all dosage groups) with a trend toward higher AUC\n            <jats:sub>0\u201324<\/jats:sub>\n            values, higher plasma concentrations at the end of the dosing interval, and a smaller volume of distribution (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05 to 0.193 for the various comparisons among dosage groups). Pharmacodynamic modeling using the residual fungal tissue burden in the main target sites as the primary endpoint and\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            , AUC\n            <jats:sub>0\u201324<\/jats:sub>\n            , time during the dosing interval of 24 h with plasma drug concentration equaling or exceeding the MIC or the minimum fungicidal concentration for the isolate, and tissue concentrations as pharmacodynamic parameters showed predictable pharmacokinetic-pharmacodynamic relationships in experimental disseminated candidiasis that fitted well with an inhibitory sigmoid maximum effect pharmacodynamic model (\n            <jats:italic>r<\/jats:italic>\n            <jats:sup>2<\/jats:sup>\n            , 0.492 to 0.819). However, no concentration-effect relationships were observed in experimental pulmonary aspergillosis using the residual fungal burden in lung tissue and survival as parameters of antifungal efficacy. Implementation of optimal plasma sampling in discriminative animal models of invasive fungal infections and pharmacodynamic modeling is a novel approach that holds promise of improving and accelerating our understanding of the action of antifungal compounds in vivo.\n          <\/jats:p>","DOI":"10.1128\/aac.45.10.2845-2855.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:55:30Z","timestamp":1027763730000},"page":"2845-2855","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":117,"title":["Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling"],"prefix":"10.1128","volume":"45","author":[{"given":"Andreas H.","family":"Groll","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Mickiene","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruta","family":"Petraitiene","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidmantas","family":"Petraitis","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caron A.","family":"Lyman","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Bacher","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Surgery Branch, Veterinary Resources Program, National Center for Research Resources,2 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Piscitelli","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Pharmacokinetics Research Laboratory, Pharmacy Department, Warren Grant Magnuson Clinical Center,3 National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"23","article-title":"Pharmacokinetics of antibiotics in tissues and tissue fluids: a review.","volume":"74","author":"Cars O.","year":"1991","unstructured":"Cars O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand. J. Infect. Dis. 74 (Suppl.) 1991 23 33","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.28.8.1828-1841.1990"},{"key":"e_1_3_2_4_2","unstructured":"Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources Commission on Life Sciences National Research Council\n          Guide for the care and use of laboratory animals.\n          1996\n          National Academy Press\n          Washington D.C."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01070904"},{"key":"e_1_3_2_7_2","unstructured":"D'Argenio\n              D. Z.\n              Schumitzky\n              A.\n          Adapt II user's guide.\n          1990\n          Biomedical Simulations Resource\n          University of Southern CaliforniaLos Angeles"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.48.100194.002351"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1108-1111.2000"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(96)00202-7"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.35.1.139-143.1997"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.2.356"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1358\/dof.1994.019.04.244501"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Gibaldi\n              M.\n              Perrier\n              D.\n          Pharmacokinetics\n          2nd ed.\n          1982\n          455\n          459\n          Marcel Dekker Inc\n          New York N.Y","DOI":"10.1201\/b14095"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.830"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.596-600.2001"},{"key":"e_1_3_2_17_2","unstructured":"Groll A. H. and T. J. Walsh. Caspofungin: pharmacology safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs in press."},{"key":"e_1_3_2_18_2","first-page":"405","article-title":"FK-463.","volume":"2","author":"Groll A. H.","year":"2000","unstructured":"Groll A. H. Walsh T. J. FK-463. Curr. Opin. Anti-Infect. Investig. Drugs 2 2000 405 412","journal-title":"Curr. Opin. Anti-Infect. Investig. Drugs"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60129-5"},{"key":"e_1_3_2_20_2","first-page":"353","article-title":"LY-303366.","volume":"1","author":"Hawser S.","year":"1999","unstructured":"Hawser S. LY-303366. Curr. Opin. Anti-Infect. Investig. Drugs 1 1999 353 360","journal-title":"Curr. Opin. Anti-Infect. Investig. Drugs"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.6.1.1"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2576"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00144-2"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/02681219780000961"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1480"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.11.2240"},{"key":"e_1_3_2_27_2","unstructured":"NCCLS\n          Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard. NCCLS document M27-T.\n          1997\n          NCCLS\n          Wayne Pa"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2726"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2148"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2898"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.56"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.Supplement_1.S139"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1321"},{"key":"e_1_3_2_34_2","first-page":"467","article-title":"Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits.","volume":"38","author":"Walsh T. J.","year":"1988","unstructured":"Walsh T. J. Bacher P. Pizzo P. A. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38 1988 467 470","journal-title":"Lab. Anim. Med."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01117450"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.863"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.10.2845-2855.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.10.2845-2855.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:48:51Z","timestamp":1645462131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.10.2845-2855.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["10.1128\/AAC.45.10.2845-2855.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.10.2845-2855.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10]]},"assertion":[{"value":"2000-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-07-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}